1. Why Did Samsung Divest from Remed?

Officially, Samsung stated ‘investment portfolio strategy adjustment.’ However, the sale of a substantial number of shares in a short period may indicate concerns about changing market conditions or lowered expectations for Remed’s growth potential. Given the increasing macroeconomic uncertainties at the time, such as interest rate hikes in the US and Europe and rising raw material prices, it’s possible these factors influenced the decision.

2. How Strong Are Remed’s Fundamentals?

Despite a decline in sales, Remed achieved improved operating profit margins in Q1 2025 due to cost reductions and improved sales and administrative expenses efficiency.

  • Brain Rehabilitation: Positive factors include the launch of antidepressants and FDA approvals, while negative factors include clinical trial stages for Alzheimer’s/stroke treatments and intensifying competition.
  • Chronic Pain Treatment: Positive factors include FDA approval for NMS products and a favorable market response to Salus FSWT, offset by intensifying competition with BTL.
  • Aesthetics: A short-term negative is the Allergan supply disruption, but long-term growth potential exists with new product launch plans and growth in the EBD market.

3. What’s the Forecast for Remed’s Stock Price?

Samsung’s large-scale selling could negatively impact the stock price in the short term. This could lead to a decline in investor sentiment and put downward pressure on the stock. However, if Remed’s fundamentals remain strong, the impact may be limited. In the long term, the success of Remed’s US market entry and new product development strategy will likely have a greater impact on the stock price.

4. What Actions Should Investors Take?

Instead of reacting to short-term price fluctuations, investors should focus on Remed’s fundamentals and long-term growth potential. It’s crucial to analyze analyst reports to understand market expectations and continuously monitor competitor trends and changes in relationships with key customers.